In patients with stage I–II ovarian cancer, there were no significant differences in overall survival between the EpCAM-high and -low groups (Figure 5C), whereas progression-free survival was significantly different between the EpCAM-high and -low groups (Figure 5D). This evidence concerns the gene EPCAM and ovarian cancer.